Cost of Diabetes in the Kingdom of Saudi Arabia, 2014

被引:0
|
作者
Mokdad, Ali H. [1 ]
Tuffaha, Marwa [1 ]
Hanlon, Michael [1 ]
El Bcheraoui, Charbel [1 ]
Daoud, Farah [1 ]
Al Saeedi, Mohammad [2 ]
Alrasheedy, Ahmad A. [2 ]
Al Hussein, Mohammad A. [2 ]
Memish, Ziad A. [2 ]
Basulaiman, Mohammed [2 ]
AlMazroa, Mohammad A. [2 ]
Al Rabeeah, Abdullah A. [2 ]
机构
[1] Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA
[2] Minist Hlth Kingdom Saudi Arabia, Al Murabba Riyadh 12613, Saudi Arabia
关键词
Monotherapy; Diabetes; Secretagogue;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Diabetes mellitus is a major burden in the Kingdom of Saudi Arabia (KSA). We estimated the direct cost of diabetes in KSA and the future cost accounting for currently undiagnosed and borderline diabetics. Methods: We used a bottom-up approach to determine the direct cost of diabetes mellitus in KSA at the population level using Saudi Ministry of Health (MOH) cost data for medications, health visits, laboratories, and hospitals. We used Saudi Health Interview Survey (SHIS) national data to estimate the number of people categorized as gestational, those with borderline diabetes (glucose intolerant), diagnosed, undiagnosed, controlled, and uncontrolled diabetics. Results: We estimate that the current cost of diabetes is at 17 billion Riyals. We also estimate that if those who are undiagnosed joined the treatment pool, the future cost would increase to 27 billion Riyals. Moreover, we estimate that if those with glucose intolerance (pre-diabetes) progress at the current observed rate to become diabetics, the future cost would be 43 billion Riyals. Conclusion: With such a high cost, the projected growth of the Saudi population, and aging, KSA will face a tremendous strain on its human and financial resources. Prevention and control of diabetes mellitus should be the main focus in years to come.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Saudi Arabia: A Kingdom in Peril
    Pelham, Nicolas
    NEW YORK REVIEW OF BOOKS, 2016, 63 (15) : 32 - 34
  • [23] Saudi Arabia: A Kingdom in Peril
    Menshawy, Mustafa
    POLITICAL STUDIES REVIEW, 2016, 14 (04) : 633 - 634
  • [24] Ophthalmology in the Kingdom of Saudi Arabia
    Wagoner, MD
    al-Rajhi, AA
    ARCHIVES OF OPHTHALMOLOGY, 2001, 119 (10) : 1539 - 1543
  • [25] Saudi Arabia: A Kingdom in Peril
    Beaugrand, Claire
    REVUE DES MONDES MUSULMANS ET DE LA MEDITERRANEE, 2019, 145
  • [26] The price of health: unveiling the cost of diabetes treatment in Kingdom of Saudi Arabia (KSA); A systematic literature review protocol
    Kanan, Mohammed
    Alharbi, Bader
    Alshammari, Ahmed
    Alshammari, Rahaf
    Alsayed, Abrar
    Alshammari, Budur
    Aldhfiri, Norah
    Bamuflih, Mohammed
    Alkhateeb, Moussa
    Alqahtani, Reem
    Asiri, Nawal
    Alnami, Waad
    Alghaseb, Reema
    Almatrafi, Abdullah
    Jan, Raghad
    PHARMACY PRACTICE-GRANADA, 2024, 22 (03):
  • [27] Socio-economic inequalities in diabetes prevalence in the Kingdom of Saudi Arabia
    Al-Hanawi, Mohammed Khaled
    Chirwa, Gowokani Chijere
    Pulok, Mohammad Habibullah
    INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT, 2020, 35 (01): : 233 - 246
  • [28] COST-EFFECTIVENESS OF EVOLOCUMAB FOR THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLEMIA IN THE KINGDOM OF SAUDI ARABIA
    Alghamdi, A.
    Balkhi, B.
    Altowaijri, A.
    Alshehri, N.
    AlHabib, K. F.
    Ralph, L.
    Marriott, E. R.
    Perlaza, Garcia J.
    al-Janad, F.
    Aziziyeh, R.
    VALUE IN HEALTH, 2020, 23 : S95 - S96
  • [29] Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
    Alghamdi, Ahmed
    Balkhi, Bander
    Altowaijri, Abdulaziz
    Al-shehri, Nasser
    Ralph, Lewis
    Marriott, Emily-Ruth
    Urbich, Michael
    Aljanad, Fawaz
    Aziziyeh, Rima
    PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 277 - 291
  • [30] Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
    Ahmed Alghamdi
    Bander Balkhi
    Abdulaziz Altowaijri
    Nasser Al-shehri
    Lewis Ralph
    Emily-Ruth Marriott
    Michael Urbich
    Fawaz Aljanad
    Rima Aziziyeh
    PharmacoEconomics - Open, 2022, 6 : 277 - 291